Next Article in Journal
Gastroparesis in the Pediatric Patient: Children Are Not Little Adults
Previous Article in Journal
Status of Brain Imaging in Gastroparesis
Open AccessReview

Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review

1
School of Medicine, University of Minho, 4710-070 Braga, Portugal
2
Life and Health Sciences Research Institute (ICVS)/3B’s - PT Government Associate Laboratory, 4710-070 Braga/Guimarães, Portugal
3
Surgery Department, Coloproctology Unit, Braga Hospital, 4710-243 Braga, Portugal
*
Author to whom correspondence should be addressed.
These authors contributed equally for the paper.
Gastrointest. Disord. 2020, 2(2), 71-85; https://doi.org/10.3390/gidisord2020007
Received: 18 February 2020 / Revised: 29 March 2020 / Accepted: 13 April 2020 / Published: 18 April 2020
Background: the presence of liver metastasis in colorectal cancer (CRC) remains one of the most significant prognostic factors. Objective: systematically review the results of studies evaluating the benefit of adding bevacizumab to a normal chemotherapy regime in the survival of patients with colorectal-cancer liver metastasis (CRLM). Search methods: Pubmed and Google Scholar databases were searched for eligible articles (from inception up to the 2 April 2019). Inclusion criteria: studies including patients with CRLM receiving anti-vascular endothelial growth factor (VEGF; bevacizumab) as treatment, overall survival as an outcome; regarding language restrictions, only articles in English were accepted. Main results: Eleven studies met the inclusion criteria. In 73% of these cases, chemotherapy with bevacizumab was an effective treatment modality for treating CRLM, and its administration significantly extended both overall survival (OS) and/or progression-free survival (PFS). Nevertheless, three articles showed no influence on survival rates of bevacizumab-associated chemotherapy. Author conclusions: It is necessary to standardize methodologies that aim to evaluate the impact of bevacizumab administration on the survival of patients with CRLM. Furthermore, follow-up time and the cause of a patient’s death should be recorded, specified, and cleared in order to better calculate the survival rate and provide a comparison between the produced literature. View Full-Text
Keywords: anti-VEGF; colorectal cancer; hepatic metastasis; survival anti-VEGF; colorectal cancer; hepatic metastasis; survival
Show Figures

Figure 1

MDPI and ACS Style

Novo, I.; Campos, B.; Pinto-Ribeiro, F.; Martins, S.F. Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review. Gastrointest. Disord. 2020, 2, 71-85.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Back to TopTop